Nasdaq100 ETF vs Revolution Medicines Inc. Common Stock — how do they compare? Nasdaq100 ETF trades at $750.48 (market cap $506.92B), while Revolution Medicines Inc. Common Stock trades at $191.49 (market cap $40.32B). The key difference: Nasdaq100 ETF is far larger — about 12.6× Revolution Medicines Inc. Common Stock's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Revolution Medicines Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| QQQ | RVMD | |
|---|---|---|
Market Cap | $506.92B | $40.32B |
Volume | 48,326,518 | 4,855,734 |
52-Week High | $759.66 | $221.15 |
52-Week Low | $558.34 | $47.50 |
Typical Hold Time | 162 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $37.02B |
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $749.24, down 1.12% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings and mixed analyst sentiment with a 50% buy/50% sell split. Recent news highlights QQQ's tech concentration and fee comparisons with competing ETFs, while broader market concerns about AI valuations and interest rates create headwinds.
The outlook remains cautiously optimistic given strong technical momentum, though elevated tech valuations and Federal Reserve policy pose risks. QQQ's innovation-focused portfolio offers growth exposure but requires monitoring of concentration risk in the technology sector amid market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →